IVBXF (Innovent Biologics) Ending Cash Position : $236 Mil (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Innovent Biologics Ending Cash Position?

Innovent Biologics's Ending Cash Position for the quarter that ended in Jun. 2024 was $236 Mil.

Innovent Biologics's quarterly Ending Cash Position increased from Jun. 2023 ($186 Mil) to Dec. 2023 ($385 Mil) but then declined from Dec. 2023 ($385 Mil) to Jun. 2024 ($236 Mil).

Innovent Biologics's annual Ending Cash Position declined from Dec. 2021 ($213 Mil) to Dec. 2022 ($146 Mil) but then increased from Dec. 2022 ($146 Mil) to Dec. 2023 ($385 Mil).

Innovent Biologics Ending Cash Position Historical Data

The historical data trend for Innovent Biologics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Ending Cash Position Chart

Innovent Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

195.16

213.43

145.76

384.54

Innovent Biologics Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial												145.76	186.03	384.54	236.26	-

Innovent Biologics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Innovent Biologics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	142.316	+	242.224
	=	385

Innovent Biologics's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	378.47	+	-142.215
	=	236

Innovent Biologics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovent Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (OTCPK:IVBXF) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

IVBIY:USA 01801:Hong Kong 6IB:Germany

Address

168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.innoventbio.com

Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.